Literature DB >> 25450337

Modulation of TIM-3 expression on NK and T cell subsets in HIV immunological non-responders.

Sander de Kivit1, Ludwijn J R Lempsink2, Jill Plants2, Jeffrey Martinson2, Ali Keshavarzian3, Alan L Landay4.   

Abstract

Highly active antiretroviral therapy (HAART) for the treatment of HIV infection sustains viral suppression and increases CD4(+) T cells in HIV patients. However, in 10-25% of subjects, known as immunological non-responders (INRs), HAART does not increase CD4 count. We investigated a potential role for galectin-9 and TIM-3 in INRs as galectin-9 and TIM-3 have been described to modulate NK and T cell function. PBMCs were isolated from healthy controls, HIV immunological responders (IRs, >350CD4(+) cells/mm(3)) and HIV INRs (<350CD4(+) cells/mm(3)) and TIM-3 and galectin-9 expressions on NK cell subsets and CD4(+) T cells were assessed. HIV INRs and HIV IRs showed increased galectin-9 expression on CD16(-)CD56(bright) and CD16(+)CD56(+) NK cells and CD4(+) T cells. Only HIV INRs showed a reduced frequency of TIM-3-expressing CD16(+)CD56(+), CD16(+)CD56(-) and CD4(+) cells, which correlated with low peripheral CD4 counts. These data suggest that TIM-3 expression may be characteristic for HIV INRs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4(+) T cell; Galectin-9; HIV; Immunological non-responders; NK cells; TIM-3

Mesh:

Substances:

Year:  2014        PMID: 25450337     DOI: 10.1016/j.clim.2014.10.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART.

Authors:  Alexandre Girard; Delphine Vergnon-Miszczycha; Anne-Emmanuelle Depincé-Berger; Xavier Roblin; Frederic Lutch; Claude Lambert; Nicolas Rochereau; Thomas Bourlet; Christian Genin; Stéphane Paul
Journal:  J Acquir Immune Defic Syndr       Date:  2016-07-01       Impact factor: 3.731

2.  Adaptive NKG2C+CD57+ Natural Killer Cell and Tim-3 Expression During Viral Infections.

Authors:  Hassen Kared; Serena Martelli; Shu Wen Tan; Yannick Simoni; Meng Li Chong; Siew Hwei Yap; Evan W Newell; Sylvia L F Pender; Adeeba Kamarulzaman; Reena Rajasuriar; Anis Larbi
Journal:  Front Immunol       Date:  2018-04-20       Impact factor: 7.561

Review 3.  A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease.

Authors:  Olivier Lucar; R Keith Reeves; Stephanie Jost
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

4.  The inhibitory receptor Tim-3 fails to suppress IFN-γ production via the NFAT pathway in NK-cell, unlike that in CD4+ T cells.

Authors:  Xiaowen Yu; Bin Lang; Xi Chen; Yao Tian; Shi Qian; Zining Zhang; Yajing Fu; Junjie Xu; Xiaoxu Han; Haibo Ding; Yongjun Jiang
Journal:  BMC Immunol       Date:  2021-04-09       Impact factor: 3.615

Review 5.  NK Cells in HIV Disease.

Authors:  Eileen Scully; Galit Alter
Journal:  Curr HIV/AIDS Rep       Date:  2016-04       Impact factor: 5.071

6.  Reduced Expression of Galectin-9 Contributes to a Poor Outcome in Colon Cancer by Inhibiting NK Cell Chemotaxis Partially through the Rho/ROCK1 Signaling Pathway.

Authors:  Yang Wang; Jintang Sun; Chao Ma; Wenjuan Gao; Bingfeng Song; Hao Xue; Weiliang Chen; Xi Chen; Yun Zhang; Qianqian Shao; Qingjie Wang; Lei Zhao; Jia Liu; Xiuwen Wang; Huayang Wang; Yun Zhang; Meixiang Yang; Xun Qu
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240

7.  Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients.

Authors:  Hongliang Liu; Liqiang Zhi; Ning Duan; Pengxiao Su
Journal:  FEBS Open Bio       Date:  2016-07-09       Impact factor: 2.693

Review 8.  Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin.

Authors:  Yu Sun; Jie Zhou; Yongjun Jiang
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.